Stockscreener 앱 받기
3.74
2.19%
0.08
시간 외 거래:
3.73
-0.01
-0.27%
전일 마감가:
$3.66
열려 있는:
$3.61
하루 거래량:
1.41M
Relative Volume:
0.67
시가총액:
$452.87M
수익:
$7.83M
순이익/손실:
$-64.92M
주가수익비율:
-7.0606
EPS:
-0.5297
순현금흐름:
$-47.22M
1주 성능:
+6.55%
1개월 성능:
+15.79%
6개월 성능:
+95.81%
1년 성능:
+141.29%
1일 변동 폭
$3.52
$3.795
1주일 범위
$3.47
$3.94
52주 변동 폭
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.74 | 443.18M | 7.83M | -64.92M | -47.22M | -0.5297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Aclaris stock maintained at Buy by H.C. Wainwright on trial progress - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
Aclaris completes enrollment in atopic dermatitis trial By Investing.com - Investing.com Canada
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings - MarketBeat
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bitget
Aclaris Therapeutics completes enrollment in phase 2 trial of bosakitug (ATI-045) in atopic dermatitis - marketscreener.com
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis - TradingView
Aclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026 - Quiver Quantitative
109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan
Deep Track entities hold 9.35M Aclaris shares (ACRS) — 7.01% stake - Stock Titan
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Aclaris Therapeutics Raises $20 Million in Equity Financing - The Globe and Mail
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aclaris Therapeutics (NASDAQ: ACRS) sells 5.7M shares to raise $20M - Stock Titan
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline - Investing.com Canada
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com Australia
Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS) - The Globe and Mail
Aclaris: Q4 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (NASDAQ: ACRS) outlines deep immunology pipeline and 2025 losses - Stock Titan
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus - Investing.com India
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):